Scinai Immunotherapeutics (NASDAQ: SCNI) today announced the execution of a formal amendment to its finance contract with the European Investment Bank (“EIB”). According to the announcement, the amendment extends the maturity date of the contract by four years from Dec. 31, 2027, to Dec. 31, 2031. “I thank the EIB for their ongoing support and cooperation. As the lending arm of the European Union, the EIB’s mission includes providing financing to support medical research and improve health care, and to do so in a manner that provides innovative young companies not only with required resources but also sufficient time to achieve their business goals,” said Scinai’s CEO Amir Reichman. “This extension of the maturity date of our financial facility agreement recognizes the time frame required to develop our anti–IL–17 NanoAbs as a treatment for autoimmune diseases such as psoriasis and psoriatic arthritis. In particular, the extension will positively impact our financial health, thereby helping to clear the path towards developing Scinai into a company that provides significant value to patients and shareholders.”
To view the full press release, visit https://ibn.fm/3p25a
About Scinai Immunotherapeutics Ltd.
Scinai is a biopharmaceutical company with two complementary business units. These include in-house development of inflammation and immunology (“I&I”) biological products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs; and a comprehensive CDMO service to help biotech companies bring their products to market efficiently and effectively by leveraging Scinai’s GMP and non-GMP drug development and manufacturing capabilities for pre-clinical and clinical studies. For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN